AKT1 and Hepatic fibrosis: Our findings suggested that the inhibitory action of isorhamnetin against hepatic fibrosis is through the reduction of HSC-T6 cell activation, which may be due to the effect of isorhamnetin on the PI3K-Akt signaling pathway.